Click here for original published article
The progress of the global parenteral nutrition market is based on the high prevalence of chronic conditions across the globe. The rise in cancer, AIDS, diabetes, Crohn’s disease, gastro-intestinal disorders, and short bowel syndrome cases has also led a growth in the consumption of parenteral nutrition in the recent years. The World Health Organization (WHO) affirmed this fact with statistics indicating that there will be a 70% rise in the number of new cancer cases between 2025 and 2035. The Crohn’s & Colitis Foundation of America also provided grim figures indicating that there will be 70,000 new cases of Crohn’s disease each year. Thus, the rising health complications will propel the demand for parenteral nutrition across health facilities.
These supportive factors are expected to create an opportunity for this market, which will be worth US$6.9 bn by 2023 as compared to US$4.1 bn in 2014. Between the years 2015 and 2023, this market is expected to expand at a CAGR (Compound Annual Growth Rate) of 5.7%. North America Accounted for Over 40% of the Parenteral Nutrition Market in 2014. Meanwhile, the parenteral nutrition market in Asia Pacific is expected to surge at the highest pace of 7.3% CAGR (Compound Annual Growth Rate) between 2015 and 2023.
